Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data

被引：46

作者：

Dvorak, Christopher C. ^{[1
]}

Fisher, Brian T. ^{[2
]}

Sung, Lillian ^{[3
]}

Steinbach, William J. ^{[4
]}

Nieder, Michael ^{[5
]}

Alexander, Sarah ^{[3
]}

Zaoutis, Theoklis E. ^{[2
]}

机构：

[1] Univ Calif San Francisco, Div Pediat Blood & Marrow Transplant, Dept Pediat, San Francisco, CA 94143 USA

[2] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA

[3] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada

[4] Duke Univ, Div Pediat Infect Dis, Durham, NC USA

[5] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA

来源：

PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 01期

基金：

加拿大健康研究院; 美国国家卫生研究院;

关键词：

acute leukemia; hematopoietic cell transplant; invasive fungal infection; INVASIVE FUNGAL-INFECTIONS; STEM-CELL TRANSPLANTATION; LIPOSOMAL AMPHOTERICIN-B; BONE-MARROW; DOUBLE-BLIND; FLUCONAZOLE PROPHYLAXIS; NEUTROPENIC PATIENTS; RISK-FACTORS; ASPERGILLOSIS; RECIPIENTS;

D O I：

10.1002/pbc.23415

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A severe complication of the treatment of pediatric cancers is the development of an invasive fungal infection (IFI). The data to support antifungal prophylaxis in pediatric oncology patients derive primarily from adult patients, and thus the optimal agent to utilize is not clear. Fluconazole has been a standard option, but agents with antimold activity are now available, each with limitations. Pediatric dosing for voriconazole and posaconazole is uncertain and multiple drug interactions exist. The echinocandins are well-tolerated, but only available in intravenous form. Ultimately, studies demonstrating biologic risk factors for the development of IFI may lead to personalized prophylactic strategies. Pediatr Blood Cancer 2012; 59: 2126. (C) 2011 Wiley Periodicals, Inc.

引用

页码：21 / 26

页数：6

共 61 条

[1] Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia [J].

Afzal, Samina ;

Ethier, Marie-Chantal ;

Dupuis, L. Lee ;

Tang, Laureen ;

Punnett, Angela S. ;

Richardson, Susan E. ;

Allen, Upton ;

Abla, Oussama ;

Sung, Lillian .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (12) :1064-1068

[2] Pharmacology of systemic antifungal agents [J].

Ashley, Elizabeth S. Dodds ;

Lewis, Russell ;

Lewis, James S. ;

Martin, Craig ;

Andes, David .

CLINICAL INFECTIOUS DISEASES, 2006, 43 :S28-S39

[3] Infections diagnosed in the first year after pediatric stem cell transplantation [J].

Benjamin, DK ;

Miller, WC ;

Bayliff, S ;

Martel, L ;

Alexander, KA ;

Martin, PL .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (03) :227-234

[4] Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation [J].

Bochud, Pierre-Yves ;

Chien, Jason W. ;

Marr, Kieren A. ;

Leisenring, Wendy M. ;

Upton, Arlo ;

Janer, Marta ;

Rodrigues, Stephanie D. ;

Li, Sarah ;

Hansen, John A. ;

Zhao, Lue Ping ;

Aderem, Alan ;

Boeckh, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1766-1777

[5] Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases [J].

Burgos, Ana ;

Zaoutis, Theoklis E. ;

Dvorak, Christopher C. ;

Hoffman, Jill A. ;

Knapp, Katherine M. ;

Nania, Joseph J. ;

Prasad, Priya ;

Steinbach, William J. .

PEDIATRICS, 2008, 121 (05) :E1286-E1294

[6] Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients [J].

Chou, Lillian S. ;

Lewis, Russell E. ;

Ippoliti, Cindy ;

Champlin, Richard E. ;

Kontoyiannis, Dimitrios P. .

PHARMACOTHERAPY, 2007, 27 (12) :1644-1650

[7] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Winston, Drew J. ;

Perfect, John ;

Ullmann, Andrew J. ;

Walsh, Thomas J. ;

Helfgott, David ;

Holowiecki, Jerzy ;

Stockelberg, Dick ;

Goh, Yeow-Tee ;

Petrini, Mario ;

Hardalo, Cathy ;

Suresh, Ramachandran ;

Angulo-Gonzalez, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359

[8] Safety of triazole antifungal drugs in patients with cancer [J].

Cronin, Simon ;

Chandrasekar, Pranatharthi H. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (03) :410-416

[9] Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity [J].

Cunha, Cristina ;

Di Ianni, Mauro ;

Bozza, Silvia ;

Giovannini, Gloria ;

Zagarella, Silvia ;

Zelante, Teresa ;

D'Angelo, Carmen ;

Pierini, Antonio ;

Pitzurra, Lucia ;

Falzetti, Franca ;

Carotti, Alessandra ;

Perruccio, Katia ;

Latge, Jean-Paul ;

Rodrigues, Fernando ;

Velardi, Andrea ;

Aversa, Franco ;

Romani, Luigina ;

Carvalho, Agostinho .

BLOOD, 2010, 116 (24) :5394-5402

[10] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].

De Pauw, Ben ;

Walsh, Thomas J. ;

Donnelly, J. Peter ;

Stevens, David A. ;

Edwards, John E. ;

Calandra, Thierry ;

Pappas, Peter G. ;

Maertens, Johan ;

Lortholary, Olivier ;

Kauffman, Carol A. ;

Denning, David W. ;

Patterson, Thomas F. ;

Maschmeyer, Georg ;

Bille, Jacques ;

Dismukes, William E. ;

Herbrecht, Raoul ;

Hope, William W. ;

Kibbler, Christopher C. ;

Kullberg, Bart Jan ;

Marr, Kieren A. ;

Munoz, Patricia ;

Odds, Frank C. ;

Perfect, John R. ;

Restrepo, Angela ;

Ruhnke, Markus ;

Segal, Brahm H. ;

Sobel, Jack D. ;

Sorrell, Tania C. ;

Viscoli, Claudio ;

Wingard, John R. ;

Zaoutis, Theoklis ;

Bennett, John E. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821

← 1 2 3 4 5 6 7 →